You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《藍籌業績》中國生物製藥(01177.HK)半年純利12.59億元人民幣跌34.5% 派中期息2港仙
阿思達克 08-25 16:36
中國生物製藥(01177.HK)公布截至今年6月底止中期業績,營業額152.77億元人民幣(下同),按年升0.5%。純利12.59億元,按年跌34.5%;每股盈利6.78分。派中期息2港仙,上年同期派6港仙。 截至報告期日,集團有在研產品127個,其中抗腫瘤用藥60個、肝病用藥10個、呼吸系統用藥21個、外科/鎮痛用藥17個,其他類用藥19個,共涉及I類創新產品69個。 集團指,其持股15.03%、主要從事人用疫苗研發、生產和銷售的科興中維開發的新冠疫苗「克爾來福」,已向全球供應總量超29億劑。隨著市場環境不斷變化,其新冠疫苖銷量下降,財務表現低於去年同期。集團表示,未來三年,集團將有10款創新藥上市,40餘款在研創新藥或可在2030年或之前上市。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account